The lactase persistence genotype is a protective factor for the metabolic syndrome
| Autor: | Deise C. Friedrich, Fabiana M de Andrade, Marilu Fiegenbaum, Silvana de Almeida, Vanessa S. Mattevi, Sidia M. Callegari-Jacques, Mara H. Hutz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Genetics and Molecular Biology, Vol 37, Iss 4, Pp 611-615 (2014) |
| Druh dokumentu: | article |
| ISSN: | 1678-4685 1415-4757 |
| DOI: | 10.1590/S1415-47572014000500001 |
| Popis: | The Metabolic Syndrome (MetS) is defined as a pattern of metabolic disturbances, which include central obesity, insulin resistance and hyperglycemia, dyslipidemia, and hypertension. Milk has been promoted as a healthy beverage that can improve the management of MetS. Most human adults, however, down-regulate the production of intestinal lactase after weaning. Lactase encoded by the LCT gene is necessary for lactose digestion. The -13910C > T SNP (rs4988235) is responsible for the lactase persistence phenotype in European populations. We herein investigated whether the lactase persistence genotype is also associated with the MetS in subjects from a Brazilian population of European descent. This study consisted of 334 individuals (average age of 41 years) genotyped by PCR-based methods for the -13910C > T SNP. Clinical data were assessed and the genotypes were tested for their independent contribution to the MetS using chi-square tests and multiple logistic regression analysis. Univariate analyses showed that hypertension and MetS prevalence were higher in individuals with the lactase non-persistence genotype than in lactase persistence subjects. Furthermore, lactase persistence was associated with a lower risk for MetS (OR = 0.467; 95% CI 0.264-0.824; p = 0.009). These results suggest that LCT genotypes can be a valuable tool for the management of MetS treatment. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|